Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479759 | 0.79 | MAPT (0.41) | KDM4EALDH1A1NPC1LMNAPOLB | |
| SCHEMBL9479447 | 0.79 | MAPT (0.36) | NQO2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL9480297 | 0.76 | TLR8 (0.43) | KDM4EALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9481279 | 0.74 | ALDH1A1 (0.47) | KDM4EALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9480179 | 0.73 | TLR8 (0.46) | KDM4EALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9480381 | 0.72 | TLR8 (0.47) | KDM4EALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL410281 | 0.71 | MAPT (0.46) | NQO2KDM4EALDH1A1NPC1POLB | |
| SCHEMBL577848 | 0.71 | KDM4E (0.56) | NQO2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL178081 | 0.69 | TLR8 (0.42) | NQO2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL9480318 | 0.69 | MAPT (0.48) | NQO2KDM4EALDH1A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| EP-2493894-A1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | claimed |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | claimed |
| WO-2011056573-A1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-12 | — | — | WO | claimed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | claimed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | claimed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | claimed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | claimed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | claimed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | claimed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | claimed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | claimed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NQO2 130/4885KDM4E 3667/4885ALDH1A1 1082/4885 |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA2, CHRNA5 | NQO2 397/4885KDM4E 3101/4885ALDH1A1 531/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | NQO2 549/4885KDM4E 1204/4885ALDH1A1 2549/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | NQO2 130/4885KDM4E 3667/4885ALDH1A1 1082/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | NQO2 549/4885KDM4E 1204/4885ALDH1A1 2549/4885 |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA6, CHRNA5 | NQO2 406/4885KDM4E 2396/4885ALDH1A1 1011/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | NQO2 740/4885KDM4E 1358/4885ALDH1A1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.